Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition - Wikidata - wikimedia - TriplyDB

Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition

Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition

http://www.wikidata.org/entity/Q34221658

about

Role and mechanism of miR-222 in arsenic-transformed cells for inducing tumor growth Establishment and characterization of a novel ovarian clear cell carcinoma cell line, TU-OC-2, with loss of ARID1A expression.The structural basis for cancer treatment decisions.Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms.Patterns of chromosomal copy-number alterations in intrahepatic cholangiocarcinoma SWI/SNF regulates a transcriptional program that induces senescence to prevent liver cancer.Tracking the origin of simultaneous endometrial and ovarian cancer by next-generation sequencing - a case report.Potential therapeutic targets in ARID1A-mutated cancers Immunohistochemical expression of ARID1A in penile squamous cell carcinomas: a tissue microarray study of 112 cases MEGSA: A Powerful and Flexible Framework for Analyzing Mutual Exclusivity of Tumor Mutations.Genomic characterization of patient-derived xenograft models established from fine needle aspirate biopsies of a primary pancreatic ductal adenocarcinoma and from patient-matched metastatic sites ARID1A expression in early stage colorectal adenocarcinoma: an exploration of its prognostic significance.Chromatin remodeling gene AT-rich interactive domain-containing protein 1A suppresses gastric cancer cell proliferation by targeting PIK3CA and PDK1.Loss of ARID1A expression leads to sensitivity to ROS-inducing agent elesclomol in gynecologic cancer cells.Genomic and proteomic characterization of ARID1A chromatin remodeller in ampullary tumors.The biology of Hepatocellular carcinoma: implications for genomic and immune therapies.Marked for death: targeting epigenetic changes in cancer.Genomic landscape of gastric cancer: molecular classification and potential targets.(Partial) Loss of BAF250a (ARID1A) in rectovaginal deep-infiltrating endometriosis, endometriomas and involved pelvic sentinel lymph nodes.Angiopoietin-1 protects the endothelial cells against advanced glycation end product injury by strengthening cell junctions and inhibiting cell apoptosis.Mammalian SWI/SNF complexes in cancer: emerging therapeutic opportunities.Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance.Biomarkers of EBV-positive Gastric Cancers: Loss of PTEN Expression is Associated with Poor Prognosis and Nodal Metastasis.AKT inhibition is an effective treatment strategy in ARID1A-deficient gastric cancer cells.Aberrant chromatin remodeling in gynecological cancer.Genome-wide genetic and epigenetic analyses of pancreatic acinar cell carcinomas reveal aberrations in genome stability.Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine.Novel oncogene and tumor suppressor mutations in KIT and PDGFRA wild type gastrointestinal stromal tumors revealed by next generation sequencing.Dramatic response to cyclin D-dependent kinase 4/6 inhibitor in refractory poorly differentiated neuroendocrine carcinoma of the breast.Inhibition of PI3K/AKT Signaling Pathway Radiosensitizes Pancreatic Cancer Cells with ARID1A Deficiency in Vitro.TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations

P2860

Q28384556-3E77D924-81C4-4F4E-A9CE-81EDD3AC0E44 Q33362731-022206E0-7E75-4CB3-890C-0B62FAA81845 Q34365654-357156D9-90A4-4EED-B582-20DAB58CC0BF Q34528553-108D0B9B-1E47-4775-A7F5-3DACF6A488B5 Q35215602-ADBC09F2-8E37-4317-A02C-4768DFA1D69E Q36163245-2E7628A8-1D92-4359-994B-EEB70767C06E Q36254394-60EC99F9-DA9D-41FF-B49D-8D151E9D6D2C Q36358757-4F86102E-00DE-4053-9D74-56911FEBC67E Q36416461-400423D9-ED76-447A-9ABF-94A7F713A968 Q36707069-AD32BD22-8617-42B8-8E07-6192C8F67FD0 Q37086209-D17B006C-ED25-48E6-BE54-240087877608 Q37196672-1D9F0079-EE22-48B1-B7FE-4526C020B19D Q37564670-73BE9FE4-E85E-4EB7-87C9-3EF6482519EC Q37636724-97C00AF9-042D-4A5D-887E-ED5685EA4128 Q37743503-19986972-CCAB-47E3-8C55-4DD4321B00A2 Q38635474-10CBB427-D961-4897-827D-16D7725D26A5 Q38747872-1131190C-0F13-427C-9507-EEA9F2A0579D Q38837669-2A084D2B-0D41-48C3-8F4E-BFE50164E836 Q38913558-4E637FB3-4A0F-44D1-927E-A40498FAA46D Q38924698-55C2C6B3-2789-4A81-A1EF-3A5719507063 Q39229171-831D62A3-2DF4-42C8-A2FE-2E77920B442E Q40633762-D1B9E87F-36AF-4944-AC14-EF63E597FBE0 Q40737773-A73CB828-3B90-4585-8D33-50AF8195863E Q41545361-2239F885-7ECA-444C-B15F-0E8A9867D65B Q47107325-AE07CC36-2938-4451-8625-0CC4330C61C7 Q47164606-AB40AF90-B44A-46E0-8582-283576DB64A7 Q48333251-2C502A40-0E77-4062-874B-94B01EBCC608 Q55070034-8580B809-11AF-4C2C-B5CB-0EB58985D57A Q55149532-4BDFC79F-24E2-4E5B-AD3F-988D89A3D944 Q55231951-847BEB16-27AD-4CD5-9124-56C2F946A624 Q58604367-9AC18613-21F8-4705-A55A-AEED6869F762

P2860

Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition

http://www.wikidata.org/entity/Q34221658

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition

@ast

Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition

@en

Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition

@nl

type

label

Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition

@ast

Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition

@en

Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition

@nl

prefLabel

Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition

@ast

Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition

@en

Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition

@nl

P1433

Q34221658-BBF41B10-BD54-4FA0-B6CB-6931B7C96114

P1476

Q34221658-7D5FEF52-F082-45BC-A4C2-64770C220F66

P2093

Q34221658-41B207C2-C89D-4BF7-BA85-827F78F9AE93

Q34221658-58B8C77A-AA99-4A83-82C5-597763B8DFC3

Q34221658-8FB216AC-711F-43DA-838C-E1DE564B3924

Q34221658-C32AD5B0-0478-4462-B681-CDD20AA535EF

Q34221658-F6F1C2B2-E898-4BCF-B913-AC37BDDD89E1

P2860

Q34221658-15C3269A-8C8A-4345-AB2D-271F74DD84F3

Q34221658-1CE5FEF1-7D02-4C31-B344-7EC3C070F8A7

Q34221658-4F6EA667-B632-405E-AC93-AC1BCF5B5BCA

Q34221658-5545CF9B-D0E3-4526-90F2-545AB7D58A68

Q34221658-70E37FA7-AE45-4B98-9FBC-8779338639F1

Q34221658-788F6ECE-34A6-4EDD-AB7D-370E7002C48D

Q34221658-7A262749-A6FE-4AD1-860C-F6676A30BF8D

Q34221658-7DD95F59-22A3-42B5-86E2-B382B301561A

Q34221658-8FC5EAEC-9165-432C-9E08-27D70B5371DF

Q34221658-974E0917-886B-43F3-9648-6B9BB639A24D

P304

Q34221658-6352B93A-B7A8-41D0-96DE-C5FA6923652A

P31

Q34221658-3AF7EE36-A3BE-4F11-9061-7AE23C3FB4C3

P356

Q34221658-B7B6AF0A-90D5-472E-93C1-24DA8B28B8B2

P407

Q34221658-CA2968D7-1287-4812-B273-C413226C7FF0

P433

Q34221658-F2DA19D9-91F7-4374-A792-59DB41C8F59A

P478

Q34221658-DF87909F-C8F0-4336-8290-B6DA083FCEB4

P50

Q34221658-3E3BB660-2343-4CE5-9230-FD9E1533F595

P577

Q34221658-573D2418-8B65-464A-A6BB-1CA9F7FEFA19

P698

Q34221658-3AD34B7C-9E2D-4981-A579-1C65EC78C43D

P932

Q34221658-3DBED2F4-E1B1-4BF9-9DE7-3D4C90234BBF

P356

ONCOTARGET.2092

P1433

P1476

Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition

@en

P2093

Daniel Fink

http://www.w3.org/2001/XMLSchema#string

Eleftherios P Samartzis

http://www.w3.org/2001/XMLSchema#string

Konstantin J Dedes

http://www.w3.org/2001/XMLSchema#string

Manuel Stucki

http://www.w3.org/2001/XMLSchema#string

Patrick Imesch

http://www.w3.org/2001/XMLSchema#string

P2860

The spectrum of SWI/SNF mutations, ubiquitous in human cancers

ARID1A mutations in endometriosis-associated ovarian carcinomas

Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer

Comprehensive molecular characterization of clear cell renal cell carcinoma.

PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system.

Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer

Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators

Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma

Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types.

Roles of deletion of Arid1a, a tumor suppressor, in mouse ovarian tumorigenesis

P304

5295-5303

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.2092

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24979463

http://www.w3.org/2001/XMLSchema#string

P932

4170604

http://www.w3.org/2001/XMLSchema#string